HK1256969A1 - Fungal keratitis prophylactic or therapeutic agent - Google Patents

Fungal keratitis prophylactic or therapeutic agent Download PDF

Info

Publication number
HK1256969A1
HK1256969A1 HK18116109.4A HK18116109A HK1256969A1 HK 1256969 A1 HK1256969 A1 HK 1256969A1 HK 18116109 A HK18116109 A HK 18116109A HK 1256969 A1 HK1256969 A1 HK 1256969A1
Authority
HK
Hong Kong
Prior art keywords
rapamycin
polyethylene glycol
agent
salt
keratomycosis
Prior art date
Application number
HK18116109.4A
Other languages
English (en)
Chinese (zh)
Inventor
Jinzhong Zhang
景山正明
Original Assignee
Santen Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd. filed Critical Santen Pharmaceutical Co., Ltd.
Publication of HK1256969A1 publication Critical patent/HK1256969A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK18116109.4A 2015-09-18 2016-09-13 Fungal keratitis prophylactic or therapeutic agent HK1256969A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562220847P 2015-09-18 2015-09-18
US201562220847P 2015-09-18
PCT/JP2016/077014 WO2017047597A1 (ja) 2015-09-18 2016-09-13 角膜真菌症の予防または治療剤

Publications (1)

Publication Number Publication Date
HK1256969A1 true HK1256969A1 (en) 2019-10-04

Family

ID=58288799

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18116109.4A HK1256969A1 (en) 2015-09-18 2016-09-13 Fungal keratitis prophylactic or therapeutic agent
HK18112748.0A HK1253545A1 (zh) 2015-09-18 2016-09-13 角膜真菌病的预防或治疗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18112748.0A HK1253545A1 (zh) 2015-09-18 2016-09-13 角膜真菌病的预防或治疗剂

Country Status (13)

Country Link
US (1) US10166217B2 (cg-RX-API-DMAC7.html)
EP (1) EP3351244A4 (cg-RX-API-DMAC7.html)
JP (1) JP6639364B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180053340A (cg-RX-API-DMAC7.html)
CN (1) CN108025000A (cg-RX-API-DMAC7.html)
BR (1) BR112018005305A2 (cg-RX-API-DMAC7.html)
HK (2) HK1256969A1 (cg-RX-API-DMAC7.html)
MX (1) MX393608B (cg-RX-API-DMAC7.html)
MY (1) MY183906A (cg-RX-API-DMAC7.html)
PH (1) PH12018500579A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201802091RA (cg-RX-API-DMAC7.html)
TW (1) TWI721015B (cg-RX-API-DMAC7.html)
WO (1) WO2017047597A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112957321B (zh) * 2021-03-04 2022-08-05 青岛大学附属医院 一种氧化硫酸软骨素改性的那他霉素滴眼液及其制备方法
CN114568490B (zh) * 2022-04-01 2023-12-19 眉山职业技术学院(眉山技师学院) 雷帕霉素在抑制柑橘青霉菌生长中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
EP2187743B1 (en) * 2007-08-16 2014-07-30 Santen Pharmaceutical Co., Ltd Rapamycin formulations for treatment of age related macular degeneration

Also Published As

Publication number Publication date
BR112018005305A2 (pt) 2018-10-09
HK1253545A1 (zh) 2019-06-21
EP3351244A1 (en) 2018-07-25
JP2017057199A (ja) 2017-03-23
KR20180053340A (ko) 2018-05-21
MY183906A (en) 2021-03-17
WO2017047597A1 (ja) 2017-03-23
MX393608B (es) 2025-03-24
EP3351244A4 (en) 2019-05-01
TWI721015B (zh) 2021-03-11
CN108025000A (zh) 2018-05-11
SG11201802091RA (en) 2018-04-27
US20180271841A1 (en) 2018-09-27
PH12018500579A1 (en) 2018-09-10
MX2018003381A (es) 2018-08-15
US10166217B2 (en) 2019-01-01
TW201717943A (zh) 2017-06-01
JP6639364B2 (ja) 2020-02-05

Similar Documents

Publication Publication Date Title
US11612590B2 (en) Therapeutic agent for meibomian dysfunction
US20210077487A1 (en) Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching
JP2025111556A (ja) クロファジミンの組成物、それを含む組合せ、それを調製するためのプロセス、それを含む使用及び方法
JPWO2016072440A1 (ja) 眼科用水性組成物
US10166217B2 (en) Fungal keratitis prophylactic or therapeutic agent
WO2016171152A1 (ja) 角膜障害の治療剤、改善剤または予防剤
TW201518291A (zh) 含聚乙二醇之組成物
WO2016112260A1 (en) Concise synthesis of urea derivatives of amphotericin b
JP3502574B2 (ja) 眼感染症治療用眼軟膏剤
EP3733179A1 (en) Pharmaceutical preparation containing pyridyl aminoacetic acid compound
RS63746B1 (sr) Antifungalni agensi sa pojačanom aktivnošću u kiseloj ph
KR102034243B1 (ko) 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물
WO2016196989A1 (en) Topical composition
CN108348516B (zh) 外用剂
EP3272360B1 (en) Pharmaceutical composition comprising polypeptide
JP4239036B2 (ja) 改良薬剤組成物
AU2020411442A1 (en) Aqueous suspension composition containing sirolimus or salt thereof
MXPA02003833A (es) Un metodo para tratamiento de tumores con derivados de fumagillol.
WO2018117211A1 (ja) 眼疾患の治療及び/又は予防剤
JPH10503202A (ja) アザスピラン類を用いる日和見感染の治療方法
HK40023750A (en) Therapeutic agent for meibomian gland dysfunction
HK1238174A1 (en) Ophthalmic aqueous composition
HK1235711A1 (en) Ophthalmic aqueous composition
HK1193349B (en) Inhibitor for corneal epithelial cell death, inhibitor characterized by combining hyaluronic acid and flavin adenine dinucleotide
HK1213203B (en) Therapeutic agent for meibomian dysfunction